Additional correction of OAB symptoms by two anti-muscarinics for men over 50 years old with residual symptoms of moderate prostatic obstruction after treatment with Tamsulosin

References

• Vignozzi L, Rastrelli G, Corona G, et al. Benign prostatic hyperplasia: a new metabolic disease? J Endocrinol Invest 2014. [Epub ahead of print]
   Google Scholar
• Pöyhönen A, Auvinen A, Häkkinen JT, et al. Outcomes of medical and surgical treatment for lower urinary tract symptoms (benign prostatic obstruction) – a population-based cohort study. Int J Clin Pract 2014;68:349–55
   Google Scholar
• Kaplan SA. Re: intravesical prostatic protrusion can be a predicting factor for the treatment outcome in patients with lower urinary tract symptoms due to benign prostatic obstruction treated with tamsulosin. J Urol 2014;191:157–8
   Google Scholar
• Kahokehr A, Gilling PJ. Enucleation techniques for benign prostate obstruction: which one and why? Curr Opin Urol 2014;24:49–55
   PubMedGoogle Scholar
• Bozkurt IH, Yalcinkaya F, Sertcelik MN, et al. A good alternative to indwelling catheter owing to benign prostate hyperplasia in elderly: memotherm prostatic stent. Urology 2013;82:1004–7
   PubMedGoogle Scholar
• Spångberg A, Dahlgren H. Benign prostatic hyperplasia with bladder outflow obstruction. A systematic review. Lakartidningen 2013;110:682–5
   PubMedGoogle Scholar
• Liu N, Chen M, Chen S, et al. Preventive administration of antibiotics to patients with benign prostatic hyperplasia before urodynamic examination. Zhonghua Nan Ke Xue 2013;19:996–8
   PubMedGoogle Scholar
• Masumori N, Tsukamoto T, Horita H. α1-blocker tamsulosin as initial treatment for patients with benign prostatic hyperplasia: 5-year outcome analysis of a prospective multicenter study. Int J Urol 2013;20:421–8
   PubMedGoogle Scholar
• De Mey C. Alpha1-blocker therapy for lower urinary tract symptoms suggestive of benign prostatic obstruction: what are the relevant differences in randomised controlled trials? Eur Urol 2000;38:25–39
   PubMedGoogle Scholar
• Abrams P, Chapple C, Khoury S, et al. Evaluation and treatment of lower urinary tract symptoms in older men. J Urol 2009;181:1779–87
   Google Scholar
• Oelke M, Bachmann A, Descazeaud A. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013;64:118–40
   PubMed Web of Science ®Google Scholar
• Kaplan SA, He W, Koltun WD, et al. Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms andbladder outlet obstruction: a randomized controlled trial. Eur Urol 2013;63:158–65
   PubMed Web of Science ®Google Scholar
• Masumori N, Tsukamoto T, Yanase M. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction. Adv Urol 2010;2010:205251
   Google Scholar
• Shalaby E, Ahmed AF, Maarouf A, et al. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-j stent-related lower urinary symptoms. Adv Urol 2013;2013:752382
   PubMedGoogle Scholar
• Kosilov K, Loparev S, Ivanovskaya MA, et al. Management of overactive bladder (OAB) in elderly men and women with combined, high-dosed antimuscarinics without increased side effects. UroToday Int J 2013;6:art 47
   Google Scholar
• Kosilov K, Loparev S, Ivanovskaya MA, et al. Elderly men with overactive bladder: maintenance of satisfactory therapeutic effect of administration of combined high-dosed antimuscarinics. UroToday Int J 2013;6:art 67
   Google Scholar
• Kosilov K, Loparev S, Ivanovskaya MA, et al. Maintenance of the therapeutic effect of two high-dosage antimuscarinics in the management of overactive bladder in elderly women. Int Neurourol J 2013;17:1–6
   PubMedGoogle Scholar
• Ruffion A, Marionneau N, Taïeb C, et al. Comparison of the response to I-PSS according to the mode of administration of the questionnaire: by the doctor or self-assessment by the patient. Prog Urol 2005;15:1080–4
   PubMed Web of Science ®Google Scholar
• Coyne KS, Zyczynski T, Margolis MK, et al. Validation of an overactive bladder awareness tool for use in primary care settings. Adv Ther 2005;22:381–94
   PubMed Web of Science ®Google Scholar
• Coyne KS, Margolis MK, Bavendam T, et al. Validation of a 3-item OAB awareness tool. Int J Clin Pract 2011;65:219–24
   PubMed Web of Science ®Google Scholar
• Basra RK, Cortes E, Khullar V, et al. A comparison study of two lower urinary tract symptoms screening tools in clinical practice: the B-SAQ and OAB-V8 questionnaires. J Obstet Gynaecol 2012;32:666–71
   PubMedGoogle Scholar
• Thüroff JW, Abrams P, Andersson KE, et al. EAU guidelines on urinary incontinence. Eur Urol 2011;59:387–400
   Google Scholar
• Gurpreet S, Malcolm L, Lucia D, et al. Minimum standards for urodynamic practice in the UK. Neurol Urodyn 2010;29:1365–72
   PubMedGoogle Scholar
• Wooten WJ III, Nye JA, Schuster DM, et al. Accuracy evaluation of a 3D ultrasound-guided biopsy system. Proc SPIE 2013;8671
   PubMedGoogle Scholar
• Yang SL, Tang KQ, Bai WK, et al. Effects of low-frequency ultrasound combined with microbubbles on benign prostate hyperplasia. Can Urol Assoc J 2013;7:E681–6
   Google Scholar
• Milicevic S. Tamsulosin efficiency in treatment of benign prostatic hyperplasia evaluated by determining bladder weight. Med Arh 2012;66:391–5
   Google Scholar
• Eghbali K, Shayegan MR, Kianoush S. Investigating the effect of tamsulosin on the measurement of bladder wall thickness and International Prostate Symptom Score in benign prostatic hyperplasia. Can Urol Assoc J 2013;7:E317–21
   Google Scholar